Patient baseline characteristics
| Characteristic . | N = 25 . |
|---|---|
| Age, median (range), years | 53.0 (36–79) |
| Female, n (%) | 25 (100) |
| Race, n (%) | |
| White | 16 (64) |
| Asian | 4 (16) |
| Black or African American | 1 (4) |
| Not specified | 4 (16) |
| ECOG performance status, n (%) | |
| 0 | 13 (52) |
| 1 | 11 (44) |
| Unknown | 1 (4) |
| Histology, n (%) | |
| Ductal carcinoma | 13 (52) |
| Adenocarcinoma (NOS) | 6 (24) |
| Lobular carcinoma | 3 (12) |
| Carcinoid | 2 (8) |
| Neuroendocrine | 1 (4) |
| LDH level, n (%) | |
| Normal | 11 (44) |
| Elevated | 11 (44) |
| Null | 3 (12) |
| Prior (neo)adjuvant therapy, n (%) | 17 (68) |
| Prior systemic therapies for metastatic disease, n (%) | |
| 0 | 2 (8) |
| 1 | 1 (4) |
| 2 | 2 (8) |
| 3 | 4 (16) |
| 4 | 4 (16) |
| ≥5 | 12 (48) |
| Type of prior therapy, n (%)a,b | |
| Chemotherapy | 25 (100) |
| Endocrine therapy | 22 (88) |
| Tamoxifen | 19 (76) |
| Fulvestrant | 9 (36) |
| Aromatase inhibitor | 17 (68) |
| Other investigational therapy | 7 (28) |
| Characteristic . | N = 25 . |
|---|---|
| Age, median (range), years | 53.0 (36–79) |
| Female, n (%) | 25 (100) |
| Race, n (%) | |
| White | 16 (64) |
| Asian | 4 (16) |
| Black or African American | 1 (4) |
| Not specified | 4 (16) |
| ECOG performance status, n (%) | |
| 0 | 13 (52) |
| 1 | 11 (44) |
| Unknown | 1 (4) |
| Histology, n (%) | |
| Ductal carcinoma | 13 (52) |
| Adenocarcinoma (NOS) | 6 (24) |
| Lobular carcinoma | 3 (12) |
| Carcinoid | 2 (8) |
| Neuroendocrine | 1 (4) |
| LDH level, n (%) | |
| Normal | 11 (44) |
| Elevated | 11 (44) |
| Null | 3 (12) |
| Prior (neo)adjuvant therapy, n (%) | 17 (68) |
| Prior systemic therapies for metastatic disease, n (%) | |
| 0 | 2 (8) |
| 1 | 1 (4) |
| 2 | 2 (8) |
| 3 | 4 (16) |
| 4 | 4 (16) |
| ≥5 | 12 (48) |
| Type of prior therapy, n (%)a,b | |
| Chemotherapy | 25 (100) |
| Endocrine therapy | 22 (88) |
| Tamoxifen | 19 (76) |
| Fulvestrant | 9 (36) |
| Aromatase inhibitor | 17 (68) |
| Other investigational therapy | 7 (28) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NOS, not otherwise specified.
aPatients could have received ≥1 type of prior therapy.
bNot all prior therapies are listed.